Special: This May Soon Be the Most Talked-About $3 Stock in America

  • Facebook
  • Twitter
  • Podcast

Debit spread

News can create large moves in biotechs. This was recently the case, as Benzinga reported, for Sarepta Therapeutics Inc (Nasdaq: SRPT). The news site reported, “the FDA has granted accelerated approval for its Vyondys 53, aka golodirsen — an antisense oligonucleotide — for the treatment of Duchenne muscular dystrophy,...

Updated Terms

We've revised our Terms of Service, Privacy Policy, and Cookie Policy By accepting you agree to our updated terms and policies, Please take a few minutes to read and understand them.